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Bone marrow transplantation offers two potential therapeutic advantages over more con-
ventional therapy ofleukemia. It allows more intensive treatment to be given without regard to
marrow toxicity and allows in the case of allogeneic marrow an additional immunotherapeutic
effect through graft-versus-host disease (GVHD). Initially, allogeneic transplants in HLA
matched sibling donors were only employed in end-stage patients. Although there were en-
couraging results in terms of long-term therapeutic effects, the overall mortality was pro-
hibitive. Subsequently, patients were transplanted in remission with a marked improvement in
overall survival in both acute lymphocytic leukemia and acute non-lymphocytic leukemia. The
major obstacles to further improvement in the therapeutic effects of this procedure have been
identified (i.e., GVHD, viral infection, and relapse in ALL) and are subject to intensive in-
vestigations that already show encouraging results. Syngeneic marrow transplantation is
limited for obvious reasons, but early results have shown significant therapeutic effects, in par-
ticular, in chronic myelogenous leukemia. These results have encouraged others to use
autologous bone marrow. Marrow contamination with unseen tumor cells is being approached
by pharmacologic and immunologic techniques designed to "purge" marrow of tumor cells.
Animal and initial clinical studies have been encouraging.
Bone marrow transplantation (BMT) offers two potential therapeutic advantages
over that of more conventional therapy in leukemia. First, it allows treatment with
very intensive cytoreductive therapy without regard to marrow toxicity since the
marrow infusion is able to "rescue" the patient from this otherwise lethal toxicity. In
addition, allogeneic marrow transplantation may have an immunotherapeutic effect
against residual tumor via graft-versus-host disease (GVHD).
In the present discussion, we will consider some ofthe highlights as to the present
state of the art of allogeneic, syngeneic, and autologous bone marrow transplanta-
tion in the acute leukemias and chronic myelogenous leukemia (CML). For the
theoretical, historical, and more extensive treatment of this subject the reader is
referred to several reviews [1-5].
MARROW DONOR
In all mammals studied, the major immunologic barrier to transplantation is
determined by a linear array of genes; in man these are located on chromosome 6.
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This complex of genetic material is called the major histocompatibility complex
(MHC). A series of alleles exist for loci A, B, C, and Dr that can be identified
serologically by typing (microcytotoxicity testing) the lymphocytes of the patient
and the family. In addition, a fifth locus, the D locus closely associated with Dr,
may be identified by determining reactivity(non-identity) or non-reactivity(identity)
in one-way mixed lymphocyte cultures in vitro. In simple terms, all these laboratory
tests are designed to identify the two paternal and two maternal chromosomes
(haplotypes) and their inheritance in the family. Thus, after the typing is finished a
genetic analysis is made by inspection of the data. Individuals sharing the same
haplotypes are said to be genotypically HLA identical. These individuals, of course,
differ in terms of minor histocompatibility determinants since their inheritance of
other genetic material is not identical.
Although in certain situations "mismatched" donors and even unrelated donors
may be used, herein when we consider allogeneic donors they will be genotypically
HLA identical siblings.
Marrow is collected in heparinized syringes under general anesthesia from the
posterior iliac crests in the amount of 10-20 ml/kg. The marrow is then passed
through screens of decreasing mesh size and finally transferred to an empty blood
bag. The marrow is then immediately brought to the ward and infused intravenously
(IV) without an in-line filter [6].
Since the genes that determine major blood group antigens are not located on
chromosome 6, a situation may arise where a patient with blood group 0 has a
donor who is blood group A. Currently this poses no problem since one may simply
centrifuge the collected marrow and remove the mismatched erythrocytes. This is
routinely done on our unit and in no way have the results differed therapeutically
from situations where donors with ABO compatible marrow were used [7,8].
The term syngeneic is used when the marrow donor is a monozygotic twin. When
the patient serves as his own donor, the term autologous is employed. In these situa-
tions, of course, the marrow cells share all the genetic material of the recipient and
the expected hazards as well as possible therapeutic effects of allogeneic effects are
absent.
ALLOGENEIC TRANSPLANTATION
For ethical reasons, initial marrow transplants in acute leukemia were performed
only in end-stage patients, patients who had eventually relapsed and failed to go into
another remission with the best available chemotherapy. Total body irradiation
(TBI) alone, TBI in combination with cyclophosphamide (CY) [4,91, CY alone or in
combination with busulfan (BU) [10,11] were used as preparative treatments in these
early studies. The remarkable aspects oftheseearly studies is that up to 15 percent of
such patients showed long-term leukemia-free survivals that operationally at least
appear to be cures. Unfortunately, however, earlymortality was extremelyhigh with
the majority of patients not dying of leukemia but rather from complications ofthe
treatment. Estimates of relapse rates also were in the order of 70-100 percent. The
UCLA group attempted to improve the results by an even more intensive cytoreduc-
tive treatment. Although there was a suggestion of a decreased leukemic relapse
rate, the overall survival was not improved because of treatment-related toxicity
[12]. Patients with blastic crisis (BC) with chronic myelogenous leukemia (CML)
have a notoriously poor prognosis. In a sense, they are like the end-stage patients
with acute leukemia. In one series where allogeneic marrow transplantation was per-
formed, most died of either uncontrolled leukemia or treatment complications;
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however, three of 24 such patients are living in continuous remission for 30-60
months, indicating that a small salvage rate with allogeneic BMT is also achievable
here [4].
New directions and strategies were clearly needed and about six to seven years ago
it was decided to transplant acute leukemia patients while they were in remission. It
was reasoned that such patients would be in much better condition and free ofinfec-
tion and, furthermore, there would be less of a body burden of tumor to contend
with.
The Seattle group reported a series of patients with acute lymphocytic leukemia
(ALL) who were transplanted in their second remission following preparation with
CY 60 mg/kg given on each of two successive days and followed with a single dose
ofTBI (800-1,000 rads). At the time ofthe report [131 7/22, or 32 percent, ofthe pa-
tients were surviving from two to four years free ofdisease. The majority ofpatients
[4] who failed therapy did so because of leukemia recurrence. The transplant center
at Sloan-Kettering has reported early results in a similar group of patients in second
remission, using CY in combination with hyperfractionated irradiation. Initial
results show a leukemia-free survival better than that reported by the Seattle group
[14]. Other preliminary reports wherein fractionated TBI was used in conjunction
with CY are also encouraging in this regard. Time and the addition ofmore patients
to these series is needed before one can judge the additional therapeutic effect of
fractionated radiation versus single-dose radiation. Further, the possible benefit of
transplanting poor risk ALL in first remission is being currently investigated by
several centers. Ifthe situation is similar to acute non-lymphocytic leukemia (ANL),
leukemia-free survival should be increased. Essentially all transplant groups employ
TBI in ALL. It should be noted, however, that there is no evidence that TBI must be
employed to obtain equivalent tumor control rates. One European center has sug-
gested that chemotherapeutic regimens without TBI deserve further trial in ALL in
remission [15].
In contrast with earlier series of "end-stage" patients where the majority of pa-
tients died of non-leukemic causes, leukemic relapse has been the major problem in
patients transplanted in their second or subsequent remission. This strengthens the
notion that patients in remission better withstand the rigors of cytoreduction
because of a more favorable clinical condition.
The most exciting results have been reported for patients with ANL transplanted
in first remission. The largest series ofsuch patients has been reported by the Seattle
group, using CY plus single or fractionated doses of TBI [16]. Of 58 such patients
transplanted, more than half were living in continuous complete remission with a
median duration -of greater than 34 months at the time of the report [4]. Further-
more, at that time only three of58, or 5 percent, had suffered a relapse. Subsequently,
the Seattle group compared the effects of CY with single doses of TBI versus frac-
tionated TBI [17]. Kaplan-Meier analysis suggested a survival advantage of the
fractionated regimen but reasons for this increased survival were not clear since the
incidence of acute GVHD, chronic GVHD, leukemic relapse, etc. was not statistically
different in the two groups. A number of other groups employing single or frac-
tionated TBI for transplantation ofANL in first remission have reportedtheir initial
results [18-20]. In general, their results in small series are similar or better than
reported by the Seattle group.
Our group is the only major transplant group that does not employ TBI in our
preparative regimen for transplantation in ANL without a history of CNS disease.
Based on extensive study in the rat [21-23] and studies in "end-stage" patients with
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ANL in relapse [10,11], we prepare patients with ANL with 4 mg/kg of BU given
orally on each of four successive days (total dose of 16 mg/kg), followed immediately
by CY (50 mg/kg) given on each of four consecutive days (total dose, 200 mg/kg).
Prophylaxis for CNS leukemia is provided with a course of intrathecal
chemotherapy 50-70 days following transplantation. At the time of this writing, we
have transplanted 33 patients in first, second, and third remission or early relapse.
Fifteen survive free of leukemia for 53 to 1,124 days (median, 470 days). There has
been only one relapse to date. This was in a 35-year-old male who relapsed in the
marrow 349 days following transplantation in his third remission. He was re-
transplanted using CY and fractionated TBI and survives free ofleukemia 246 days
after the second transplant and 607 days after the first transplant. It is hoped that, as
more patients are added to the series and it matures with time, comparisons can be
made to other series where TBI is employed regarding late toxicities (i.e., cataracts,
pulmonary function deficits, growth rates, sterility, malignancies, etc.).
The decision to perform marrow transplantation, particularly in first remission,
has met with some resistance and it has been argued that survival curves for
transplanted patients are not yet statistically different from survival curves of
similar patients treated only with chemotherapy 124]. Clearly this matter will not be
settled without clinical trials that prospectively comparetransplantation versus more
conventional cytoreductive therapy. It is hoped that the answer will soon be ap-
parent from several such trials that have already begun.
COMPLICATIONS OF ALLOGENEIC MARROW TRANSPLANTATION
The most serious complications following allogeneic marrow transplantation are
viral infections in the form of gastroenteritis and interstitial pneumonitis and acute
and chronic GVHD.
During the first month following transplantation, patients are highly susceptible
to bacterial infections, particularly thosegram-negative in origin. Patients in "good"
clinical condition (i.e., in remission) areable to weather this period much better than
the"end-stage" patients. The appropriate use of some ofthe newer antibiotics, isola-
tion procedures, and judicious use of granulocyte transfusions have markedly de-
creased the severity of these complications (unless complicated by severe acute
GVHD). Currently, mortality from bacterial infection is less than 5 percent in our
center.
Following marrow transplantation, there is a severe combined immunodeficiency
that, in its gradual repair, mimics what one would expect in a recapitulation of on-
togeny [25]. We have found both B-cell, T-helper cell and T-supressor cell abnor-
malities [26]. It is, therefore, not surprising that these patients are, for a variable
length oftime, susceptible to life-threatening fungal (i.e., candidiasis, aspergillosis),
protozoan (Pneumocystis Carinii), and viral infections [herpes simplex (HSV),
cytomegalic virus (CMV) and varicella zoster (VZV)]. Despite the use of Am-
photericin B, fungal infections account for 10 percent of deaths. The problem of
Pneumocystis Carinii has largely been eliminated with the use of trimethoprim-
sulfamethoxazole. Similarly, the morbidity and mortality from HSV infections
should, in the future, be markedly decreased with the use of acyclovir [27].
Interstitial pneumonitis, 60 percent of which are associated with CMV, remains a
particularly serious problem in most transplant centers. The incidence in various
centers is 30 to 50 percent ofallogeneic transplants with a fatality of 50-60 percent.
Preliminary observations from our own group suggest that it is less in those patients
who have received BU and CY or fractionated TBI as opposed to single high doses
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of TBI [unpublished observations]. Recent observations from our center indicate
that the prognosis ofCMV infections correlates with cytotoxic T and other cytotoxic
cell responses [28]. Efforts to augment these responses by direct or indirect measures
should, in the future, decrease the mortality from this complication.
GRAFT-VERSUS-HOST DISEASE
Acute GVHD remains a major cause of morbidity and mortality following
allogeneic marrow transplantation, despite the use of genotypical HL-A identical
sibling donors and post-transplant immunosuppression with methotrexate (MTX) or
CY. This iatrogenic disease shows a varied clinical spectrum ranging from a mild
skin rash to severe involvement of the skin, gut, liver, and bronchial mucosa.
Depending upon its severity it is also associated with profound immunodeficiency
and susceptibility to opportunistic infections. Severe acute GVHD may occur in
30-50 percent of patients with a mortality of 30 to 60 percent.
Acute GVHD has been well studied in animal models. It is clear that the disease is
initiated by cytotoxic T cells reactive to host minor antigens. On the basis of studies
in a variety of species, it appears to be a self-limited disease from which individuals
may recover if they are able to survive the critical period when immunologic
defenses and anatomic (i.e., skin and gut) barriers are broken and susceptible to in-
vasion by bacterial, mycotic, and viral agents. Eventually specific suppressor cells of
T lymphocyte origin arise that are able to terminate the generation of new cytotoxic
T cells [29]. Animal studies suggest that at least some thymic function is required
for amplification of the T suppressor response [29].
Treatment of the disease with steroids and/or antithymocyte globulin, although
partially successful, is far from satisfactory. A more rational approach would be a
prophylactic treatment to prevent the disease. The aim ideally would be to prevent
the development of cytotoxic T-cell responses and yet permit the development of
specific T suppressor responses. Cyclosporin A, a novel immunosuppressant agent,
appears to be an agent capable of accomplishing this aim in rodents [30]. Clinical
studies with Cyclosporin are currently under way at several centers [31,32].
Another promising approach being evaluated in several centers is to attempt to rid
the marrow inoculum of post-thymic T cells that initiate acute GVHD. A variety of
physical, immunologic (i.e., monoclonal antibodies), and pharmacologic methods
are being vigorously pursued, some showing initial clinical promise. For a more
complete discussion of this fascinating subject the reader is referred to other reviews
[33].
A chronic form of GVHD has been recognized in 25 to 40 percent of patients
undergoing allogeneic marrow transplantation. The disease is polymorphous in
nature and has a number of clinical manifestation similar to the collagen vascular
disorders: dyspigmentation, scleroderma-like lesions of the skin, mucositis, malab-
sorption, and pulmonary insufficiency. Chronic GVHD appears to represent a
severe imbalance of humoral and cellular immunity without the fine control system
that regulates a normal immune response. Less is known about the mechanisms in-
volved in chronic as opposed to acute GVHD; however, it is a subject of intense in-
vestigation both in the laboratory and clinic Mortality in this disease used to be as
high as 80 percent, primarily because of the associated immunodeficiency and death
due to gram-positive organisms. Currently this mortality has been reduced to about
10 percent with empiric treatment with corticosteroids and azathioprine [34] which
appears to restore immunologic balance in the majority of cases.
With the variety of approaches being taken, it is this author's opinion that the
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Paradoxically this may create new problems. For instance, it has been shown that
GVHD may have atherapeutic effect in preventing clinical relapse of leukemia. Will
leukemic relapses be increased if the practical problems of GVHD are solved? In an-
ticipation ofan affirmative answer to this question, efforts in laboratory models are
being directed towardreplacing the therapeutic effect of GVHD with alternative im-
munologic or chemotherapeutic treatments.
SYNGENEIC MARROW TRANSPLANTATION
Marrow transplantation with monozygotic twin donors (syngeneic) offers a uni-
que opportunity to study transplantation without the problems associated with
GVHD. A series of 34 such patients with refractory leukemia in relapse (18 ALL, 16
ANL) have been transplanted following treatment with CY and single-dose TBI
[35]. Recurrence of leukemia (13 ALL and 10 ANL) was the principal cause of
death. Three patients with ALL and five with ANL remain in complete remission
without maintenance therapy from 29 to 103 months. Mortality in this group due to
non-leukemic causes is much reduced over that seen in a similar allogeneic series;
however, this is balanced by the increase in leukemic relapse due to the absence of
GVH.
The possible therapeutic effect of GVH in ANL is strongly suggested by the fact
that of 20 cases of ANL known to the author [unpublished observations] trans-
planted in their first remission using monozygotic twin donors, 10 of 20, or 50 per-
cent, have relapsed as compared to the 5 percent seen in the Seattle series of allo-
geneic BMT for ANL in first remission.
Patients with CML in BC have a poor prognosis; however, one of six such pa-
tientsgiven an identical-twin transplant survives in continuous unmaintained remis-
sion for 52 months [4]. Thetransplantation of such patients in the chronic phase of
their disease using identical twin donors, however, has demonstrated remarkable
results with 10 of 12 such patients showing complete continuous remission, free of
Ph' positive cells for 9 to 53 months (median 21) [36]. These results suggest that an
additional therapeutic effect of GVHD may not be required in all malignancies in
order to obtain long-term disease-free survival and possible cure. Encouraged by
these results, allogeneic transplantation in the chronic phase of CML has begun at
several centers. Initial results appear promising [33].
AUTOLOGOUS MARROW TRANSPLANTATION
Currently there is a fair amount of interest in autologous marrow transplantation
partly because of the results of allogeneic marrow transplantation but more so
because of what can be accomplished with syngeneic transplants. The technology
and early results of clinical trials are presented in recent reviews [37-41).
Although somepatients with acute leukemia have been transplanted with marrow
obtained in initial remission and cryopreserved without further treatment, none
have exhibited prolonged disease-free survival equivalent to that seen in syngeneic
transplants. An analysis of actuarial leukemia-free survival from data pooled from
several centers showed amedian duration ofremission offour to six months with no
evidence of a plateau of long-term disease-free survivors [42]. This suggests the
autologous marrow may contain viable leukemic cells. It would appear, therefore,
that an important requirement for autologous marrow transplantation in acute
leukemia would be the use ofmarrow that has been "purged" of tumor cells prior to
cryopreservation.
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Elsewhere, we have reviewed details of studies in animal model systems that in-
dicated it was possible to "purge" tumor cells from marrow by pharmacologic or im-
munologic methods [40]. We, for instance, were able to show that a congener ofCY,
4-hydroperoxycyclophosphamide (4HC) was able to eliminate tumor cells from a
marrow-tumor cell suspension with a short in vitro incubation without inhibiting the
ability ofthis treated marrow to protect irradiated rats from lethal aplasia [43]. Cur-
rently we are engaged in a phase I study designed to determine the maximum concen-
tration of 4HC that can be used for in vitro incubation without destroying the
capacity of the marrow to effect hematologic recovery after otherwise lethal inten-
sive cytoreductive therapy. So far, early results indicate that satisfactory hemato-
logic recovery may be obtained at drugconcentrations that inhibit over 90 percent of
the marrow colony forming units in culture (CFU-c) [44]. The current concentra-
tions are several orders of magnitude above what is even feasible if given in vivo.
Immunologic approaches to the elimination of tumor cells in vitro have also been
successful in animal model systems. Marrow-tumor cell mixtures have been in-
cubated with ordinary antibody (prepared in other species) and complement and
more recently with monoclonal antibodies and complement. Recently a number of
clinical trials have begun with this approach [33]. Although this method appeals to
theintellect because ofits simplicity and specificity and offers theexciting possibility
of increasing its therapeutic effect by coupling a toxin to the antibody, the phar-
macologic approach may indeed turn out to be more practical. Theoretically, all one
needs to do is to destroy all the tumor cells without destroying the restorative prop-
erties ofhematopoietic stem cells. It may make little difference whether or not other
cells in the marrow infusate are destroyed.
CONCLUSIONS
Prior studies have established that marrow transplantation is the treatment of
choice for severe aplastic anemia and severe combined immunodeficiency. Current
clinical results suggest that marrow transplantation in acute leukemia is at the very
least a viable option for the patient. Most of the major obstacles for a successful
outcome have been identified and solutions arebeing actively pursued. With the cur-
rent pace of laboratory and clinical research in this area, it seems reasonable to
predict that marrow transplantation will become the treatment of choice for acute
leukemia early on in the disease.
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